Literature DB >> 35254839

Threshold for the pleasurable effects of nicotine are lower than its reinforcing effects during self-administration.

R Ross MacLean1, Tore Eid2, Suprit Parida1, Ralitza Gueorguieva3, Elise E DeVito1, Mehmet Sofuoglu1.   

Abstract

A recent study demonstrated that during a single sampling period, 0.1 mg of intravenous (IV) nicotine (vs. placebo) was found to be the threshold for subjective and physiological drug effects. The present study is a secondary analysis evaluating whether the threshold for subjective and physiological effects is similar when the subject has repeated opportunities to choose blinded doses of nicotine versus placebo. We also examined whether cigarette craving, withdrawal, and rate of nicotine metabolism affected nicotine reinforcement, defined by a greater number of nicotine choices than placebo. Young adult (n = 34; 68% male), daily smokers had five laboratory sessions after overnight abstinence. After sampling an IV dose of nicotine (0.0125, 0.025, 0.05, 0.1, or 0.2 mg/70 kg) versus saline (placebo), participants completed a nicotine self-administration (NSA) procedure that included 10 opportunities to self-administer IV dose of nicotine or placebo. The threshold for subjective positive effects of nicotine during the NSA was equal to or lower than the sampling period, 0.05-0.1 mg versus 0.1 mg. The threshold for nicotine-induced heart rate increase was higher during the NSA than during the sampling period (0.2 mg vs. 0.1 mg). Higher baseline craving and nicotine metabolite ratio (NMR) were associated with nicotine reinforcement at 0.2 mg and 0.1 mg doses, respectively (p < .05). The results suggest that subjective effects during NSA are reported at doses lower than the sampling period. Taken together, tobacco products thought to be subthreshold for reinforcement should be carefully evaluated for their subjective effects, including their discriminative stimulus effects. (PsycInfo Database Record (c) 2022 APA, all rights reserved).

Entities:  

Year:  2022        PMID: 35254839      PMCID: PMC9448824          DOI: 10.1037/pha0000556

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.492


  36 in total

1.  Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Authors:  Eric C Donny; Rachel L Denlinger; Jennifer W Tidey; Joseph S Koopmeiners; Neal L Benowitz; Ryan G Vandrey; Mustafa al'Absi; Steven G Carmella; Paul M Cinciripini; Sarah S Dermody; David J Drobes; Stephen S Hecht; Joni Jensen; Tonya Lane; Chap T Le; F Joseph McClernon; Ivan D Montoya; Sharon E Murphy; Jason D Robinson; Maxine L Stitzer; Andrew A Strasser; Hilary Tindle; Dorothy K Hatsukami
Journal:  N Engl J Med       Date:  2015-10       Impact factor: 91.245

2.  Self-administration of intravenous nicotine in male and female cigarette smokers.

Authors:  Mehmet Sofuoglu; Sonah Yoo; Kevin P Hill; Marc Mooney
Journal:  Neuropsychopharmacology       Date:  2007-05-30       Impact factor: 7.853

3.  Non-smokers show acute tolerance to subcutaneous nicotine.

Authors:  M A Russell; M J Jarvis; G Jones; C Feyerabend
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 4.  A cognitive model of drug urges and drug-use behavior: role of automatic and nonautomatic processes.

Authors:  S T Tiffany
Journal:  Psychol Rev       Date:  1990-04       Impact factor: 8.934

Review 5.  The Use of the Nicotine Metabolite Ratio as a Biomarker to Personalize Smoking Cessation Treatment: Current Evidence and Future Directions.

Authors:  Scott D Siegel; Caryn Lerman; Alex Flitter; Robert A Schnoll
Journal:  Cancer Prev Res (Phila)       Date:  2020-03

6.  Chronic and acute tolerance to the heart rate effects of nicotine.

Authors:  K A Perkins; L H Epstein; R L Stiller; B L Marks; R G Jacob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  FKBP5 variation is associated with the acute and chronic effects of nicotine.

Authors:  K P Jensen; A I Herman; M E Morean; H R Kranzler; J Gelernter; M Sofuoglu
Journal:  Pharmacogenomics J       Date:  2014-12-23       Impact factor: 3.550

8.  Mu-opioid self-administration vs passive administration in heroin abusers produces differential EEG activation.

Authors:  Mark K Greenwald; Timothy A Roehrs
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

9.  Comparing the physiological and subjective effects of self-administered vs yoked cocaine in humans.

Authors:  Eric C Donny; George E Bigelow; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2006-03-21       Impact factor: 4.530

10.  Threshold dose for intravenous nicotine self-administration in young adult non-dependent smokers.

Authors:  R Ross MacLean; Elise E DeVito; Tore Eid; Suprit Parida; Ralitza Gueorguieva; Mehmet Sofuoglu
Journal:  Psychopharmacology (Berl)       Date:  2021-04-01       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.